VÃ©ronique Minard-Colin

List of Publications by Year
in descending order

84 papers	2,623 citations	218677 26 h-index	214800 47 g-index
85 all docs	85 docs citations	85 times ranked	3203 citing authors

#	Article	IF	Citations
1	Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group. Pediatric Blood and Cancer, 2022, 69, e29376.	1.5	3
2	Robotic Surgery in Pediatric Oncology: Lessons Learned from the First 100 Tumorsâ€"A Nationwide Experience. Annals of Surgical Oncology, 2022, 29, 1315-1326.	1.5	17
3	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	2.8	24
4	Localised rhabdomyosarcoma in infants (<12 months) and young children (12â€"36 months of age) treated on the EpSSG RMS 2005 study. European Journal of Cancer, 2022, 160, 206-214.	2.8	8
5	Reply to H. B et al. Journal of Clinical Oncology, 2022, , JCO2102612.	1.6	1
6	Intraâ€•and extraâ€€ranial <scp>BCORâ€ITD</scp> tumours are separate entities within the <scp>BCOR</scp>â€€rearranged family. Journal of Pathology: Clinical Research, 2022, 8, 217-232.	3.0	10
7	Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study. Haematologica, 2022, 107, 2173-2182.	3.5	8
8	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. International Journal of Radiation Oncology Biology Physics, 2022, 113, 602-613.	0.8	11
9	Reply to R. Lakhotia et al. Journal of Clinical Oncology, 2022, , JCO2102912.	1.6	0
10	Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents. Pediatric Blood and Cancer, 2022, 69, e29460.	1.5	13
11	Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies. Pediatric Blood and Cancer, 2022, 69, e29739.	1.5	4
12	Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement. Haematologica, 2022, 107, 2255-2260.	3.5	5
13	Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. Journal of Clinical Oncology, 2022, 40, 3730-3740.	1.6	22
14	Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. Cancers, 2022, 14, 3247.	3.7	4
15	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. European Journal of Cancer, 2022, 172, 367-386.	2.8	19
16	Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: aÂreport from the European paediatric Soft tissue sarcoma Study Group. European Journal of Cancer, 2022, 172, 119-129.	2.8	4
17	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. Pediatric Blood and Cancer, 2021, 68, e28832.	1.5	13
18	Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. International Journal of Radiation Oncology Biology Physics, 2021, 109, 231-241.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. Bulletin Du Cancer, 2021, 108, 163-176.	1.6	7
20	Should treatment of ALKâ€positive anaplastic large cell lymphoma be stratified according to minimal residual disease?. Pediatric Blood and Cancer, 2021, 68, e28982.	1.5	6
21	Head and neck tumors in children and adolescents: Impact of a multidisciplinary tumor board. Oral Oncology, 2021, 114, 105145.	1.5	11
22	Primary postâ€transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. British Journal of Haematology, 2021, 193, 1178-1184.	2.5	11
23	Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience. European Journal of Cancer, 2021, 146, 21-29.	2.8	20
24	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. American Journal of Surgical Pathology, 2021, 45, 854-867.	3.7	12
25	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers, 2021, 13, 2075.	3.7	23
26	Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered. Strahlentherapie Und Onkologie, 2021, 197, 690-699.	2.0	1
27	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSÃ©-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, 53-62.	2.8	33
28	Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death and Disease, 2021, 12, 713.	6.3	29
29	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) â€“ RMS2005 study. European Journal of Cancer, 2021, 151, 84-93.	2.8	21
30	PAX3â€NCOA1 alveolar rhabdomyosarcoma of the tongue: A rare entity with challenging diagnosis and management. Pediatric Blood and Cancer, 2021, 68, e29288.	1.5	2
31	Locally aggressive rarely metastazing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network. European Journal of Surgical Oncology, 2021, , .	1.0	2
32	ASO Visual Abstract: Robotic Surgery in Pediatric Oncologyâ€”Lessons Learned from the First 100 Tumors: A Nationwide Experience. Annals of Surgical Oncology, 2021, 28, 730-731.	1.5	0
33	Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial. Journal of Clinical Oncology, 2021, 39, 2979-2990.	1.6	38
34	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2021, 39, 3716-3724.	1.6	18
35	CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy. Cancers, 2021, 13, 5487.	3.7	9
36	Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcomaâ€”The French Experience. Frontiers in Pediatrics, 2021, 9, 783754.	1.9	2

#	ARTICLE	IF	CITATIONS
37	Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. Cancer, 2020, 126, 823-831.	4.1	21
38	Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors. Neuron, 2020, 108, 1025-1044.	8.1	31
39	Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience. Pediatric Blood and Cancer, 2020, 67, e28486.	1.5	19
40	In childhood mature B-NHL with CNS disease, patients with blasts in cerebrospinal fluid are at higher risk of failure. Blood Advances, 2020, 4, 3621-3625.	5.2	2
41	Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. European Journal of Cancer, 2020, 137, 183-192.	2.8	28
42	Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSGâ€RMS2005 study. Cancer Medicine, 2020, 9, 7580-7589.	2.8	16
43	Rituximab for High-Risk, Mature B-Cell Non-Hodgkinâ€™s Lymphoma in Children. New England Journal of Medicine, 2020, 382, 2207-2219.	27.0	157
44	Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. Cancer Medicine, 2020, 9, 2698-2709.	2.8	28
45	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	2.8	52
46	Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). European Journal of Cancer, 2020, 127, 123-129.	2.8	71
47	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. European Journal of Cancer, 2020, 130, 72-80.	2.8	18
48	SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. American Journal of Surgical Pathology, 2020, 44, 607-616.	3.7	37
49	Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1566-1575.	10.7	161
50	Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult nonâ€Hodgkin lymphoma. British Journal of Haematology, 2019, 185, 1111-1124.	2.5	7
51	Outcome of relapse in children and adolescents with Bâ€cell nonâ€Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. Pediatric Blood and Cancer, 2019, 66, e27873.	1.5	25
52	Roboticâ€assisted laparoscopic management of renal tumors in children: Preliminary results. Pediatric Blood and Cancer, 2019, 66, e27867.	1.5	36
53	Desmoid-type fibromatosis of the head and neck in children: A changing situation. International Journal of Pediatric Otorhinolaryngology, 2019, 123, 33-37.	1.0	10
54	Outcome of localized liverâ€bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Softâ€Tissue Sarcoma Study Group (EpSSG)â€RMS 2005 study. Pediatric Blood and Cancer, 2019, 66, e27725.	1.5	11

#	ARTICLE	IF	CITATIONS
55	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. European Journal of Cancer, 2019, 110, 74-85.	2.8	39
56	Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience. Cancer Medicine, 2018, 7, 1384-1393.	2.8	22
57	Melanotic neuroectodermal tumor of infancy (MNTI) of the head and neck: A French multicenter study. Journal of Cranio-Maxillo-Facial Surgery, 2018, 46, 201-206.	1.7	36
58	Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatric Blood and Cancer, 2018, 65, e26902.	1.5	44
59	Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. Cancer, 2018, 124, 1016-1024.	4.1	25
60	Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. Journal of Clinical Oncology, 2018, 36, 3466-3476.	1.6	21
61	Localized vaginal/uterine rhabdomyosarcomaâ€"results of a pooled analysis from four international cooperative groups. Pediatric Blood and Cancer, 2018, 65, e27096.	1.5	40
62	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 19, 1061-1071.	10.7	137
63	Testicular transposition in children undergoing brachytherapy for bladder and/or prostate rhabdomyosarcoma. Journal of Pediatric Surgery, 2018, 53, 1428-1431.	1.6	13
64	Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).. Journal of Clinical Oncology, 2018, 36, LBA2-LBA2.	1.6	23
65	Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 352-359.	0.8	47
66	The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. The Lancet Child and Adolescent Health, 2017, 1, 284-292.	5.6	43
67	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clinical Cancer Research, 2017, 23, 6101-6112.	7.0	102
68	Pulsed-dose rate brachytherapy for pediatric bladder prostate rhabdomyosarcoma: Compliance and early clinical results. Radiotherapy and Oncology, 2017, 124, 285-290.	0.6	20
69	Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. Head and Neck, 2017, 39, 24-31.	2.0	20
70	Quality of life and functional outcome of male patients with bladderâ€"prostate rhabdomyosarcoma treated with conservative surgery and brachytherapy during childhood. Brachytherapy, 2016, 15, 306-311.	0.5	30
71	Les anticorps monoclonaux dirigÃ©s contre les checkpoints immunologiquesÂ: de nouvelles approches dâ€™immunothÃ©rapie en onco-hÃ©matologie. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2016, 4, 5-12.	0.1	4
72	Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood, 2016, 127, 1886-1895.	1.4	33

#	ARTICLE	IF	CITATIONS
73	Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen.. Journal of Clinical Oncology, 2016, 34, 10507-10507.	1.6	62
74	Late toxicity of brachytherapy after female genital tract tumors treated during childhood: Prospective evaluation with a long-term follow-up. Radiotherapy and Oncology, 2015, 117, 206-212.	0.6	19
75	Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and imageâ€defined risk factors. Pediatric Blood and Cancer, 2015, 62, 257-261.	1.5	50
76	Imageâ€defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intraâ€operative risk factors and the completeness of resection. Pediatric Blood and Cancer, 2015, 62, 1543-1549.	1.5	61
77	Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Societe Francaise des Cancers de l'Enfant study. Haematologica, 2015, 100, 810-817.	3.5	58
78	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. European Journal of Cancer, 2015, 51, 2386-2395.	2.8	32
79	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. Journal of Clinical Oncology, 2015, 33, 2963-2974.	1.6	202
80	Urachal rhabdomyosarcoma in childhood: a rare entity with a poor outcome. Journal of Pediatric Surgery, 2015, 50, 1329-1333.	1.6	14
81	Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma â€“ A report from the SociÃ©tÃ© FranÃ§aise des Cancers et leucÃ©mies de lâ€™Enfant et de lâ€™adolescent (SFCE). European Journal of Cancer, 2012, 48, 2409-2416.	2.8	57
82	A Mendelian Predisposition to B Cell Lymphoma Caused by IL-10R2 Deficiency. Blood, 2012, 120, 5092-5092.	1.4	0
83	Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcÎ³RI, FcÎ³RIII, and FcÎ³RIV. Blood, 2008, 112, 1205-1213.	1.4	214
84	Longâ€term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladderâ€“prostate rhabdomyosarcoma: A singleâ€team experience. Pediatric Blood and Cancer, 0, , e29532.	1.5	5